Biology • Year 12 • Module 6 • Lesson 8
Biotechnology: Definitions, Scope and Historical Trajectory
Build HSC band 5–6 extended-response technique on the scope of biotechnology, the past-present-future trajectory, and the bridging case study of insulin production.
1. Stimulus-based extended response — Humulin and the 1982 turning point (Band 5–6)
8 marks Band 5–6
Stimulus. Before 1982, virtually all therapeutic insulin used to treat type 1 diabetes was extracted from the pancreases of slaughtered cattle and pigs — a traditional biotechnology dating to the 1920s. Animal insulin worked but differed from human insulin by 1–3 amino acids, occasionally triggering immune reactions, and supply was tied to the meat industry. In 1978 Genentech announced it had inserted the human insulin gene into Escherichia coli, and in 1982 the US FDA approved Humulin — the first recombinant DNA pharmaceutical for human use. By 2000 over 90% of insulin sold globally was recombinant; today, several long-acting recombinant analogues (e.g. insulin glargine) are also produced in engineered yeast and bacterial systems. The Humulin approval is often cited as the moment biotechnology “crossed the line” from a traditional to a molecular industry.
Q1. Analyse and evaluate the Humulin case as an example of the historical trajectory of biotechnology described in Lesson 8. In your response you must:
- Define biotechnology and link the definition explicitly to both traditional and modern practice.
- Explain why animal-derived insulin is itself a form of biotechnology, even though it predates recombinant DNA.
- Compare the animal-derived and recombinant pipelines on at least three criteria (e.g. molecular precision, scalability, supply chain, immunogenicity).
- Use the Humulin case to support or qualify the claim that modern biotechnology is an extension of older biological problem-solving, not a replacement.
- Reach a justified overall judgement.
2. Stimulus + data response — biotechnology across multiple sectors (Band 5–6)
8 marks Band 5–6
Stimulus. A Year 12 student writes: “Biotechnology is basically just CRISPR. Old practices like brewing or farming should not really count, because they don’t involve any genetic technology.” The student presents the table below to argue that “real” biotechnology is concentrated in only one or two sectors, and that the syllabus framing of traditional biotechnology is outdated.
| Sector | Example product / process | Approx. global market value (USD bn, 2023) | Method classification |
|---|---|---|---|
| Medicine | Recombinant insulin, mRNA vaccines, monoclonal antibodies | ~520 | Modern |
| Agriculture | Insect-resistant Bt cotton, marker-assisted breeding, selective breeding of livestock | ~125 | Mixed (traditional + modern) |
| Industry | Industrial enzymes for detergents, biofuels, bioplastics | ~95 | Mixed (fermentation + recombinant) |
| Food & beverage | Bread, beer, wine, yoghurt, cheese, soy sauce | ~70 | Traditional fermentation |
| Environmental | Bioremediation of oil spills, wastewater treatment microbes | ~38 | Mixed |
Source: indicative figures synthesised from Grand View Research and OECD biotechnology statistics, 2023.
Q2. Evaluate the student’s claim using the data and Lesson 8 content. In your response you must:
- Define biotechnology at the level used by the syllabus.
- Use at least three rows from the table to test the student’s claim quantitatively (state percentages or ratios from the data).
- Use named examples from at least three different sectors to illustrate the scope of biotechnology.
- Explain why excluding traditional biotechnology would distort later evaluations of biodiversity and ethics.
- Reformulate the student’s claim into a biologically defensible statement that aligns with the lesson’s past–present–future framing.
Q1 — Sample Band 6 response (8 marks), annotated
Biotechnology is the use of living organisms, cells or biological processes to make products or solve problems in agriculture, medicine and industry. It includes both traditional practices (fermentation, selective breeding, animal-derived products) and modern molecular techniques (recombinant DNA, gene editing, cloning) — the syllabus treats both as the one field because both deliberately direct biological systems toward human purposes. [1 — definition with both branches]
Animal-derived insulin is itself biotechnology: pancreatic insulin was extracted, purified and standardised from cattle and pig tissue and used to keep type 1 diabetic patients alive from the 1920s onwards. It deliberately uses a biological system (the mammalian pancreas) to produce a useful product for human health, which is the syllabus definition of biotechnology in the traditional sense. [1 — explains animal-derived insulin as traditional biotech]
The two pipelines differ on several key criteria. Molecular precision: recombinant Humulin is structurally identical to human insulin, while animal insulin differs by 1–3 amino acids, occasionally provoking an immune response in patients. Scalability: animal-derived production is bounded by the supply of slaughtered pancreases (about 50 pancreases for one diabetic patient’s annual supply), whereas recombinant E. coli cultures can be expanded in bioreactors independently of livestock numbers. Supply chain and ethics: recombinant production decouples insulin from the meat industry and reduces variability between batches. [1 — molecular precision criterion; 1 — scalability + supply criterion]
Humulin therefore represents a turning point in the trajectory of biotechnology: the first time human therapeutic protein was made by direct DNA manipulation of a microbe. By 2000 over 90% of insulin sold globally was recombinant, which superficially looks like a replacement. [1 — locates Humulin in the past–present–future trajectory]
However, the lesson’s claim that modern biotechnology extends rather than replaces traditional methods is still supported. Recombinant insulin still relies on biological systems — the engineered bacteria or yeast cells themselves — and is built on top of the same medical, microbial and fermentation infrastructure that traditional biotechnology developed. Many countries still use animal-derived insulin in some contexts (cost, availability), and the broader insulin industry depends on fermentation engineering inherited from traditional industries such as brewing. [1 — uses Humulin to evaluate the "extension not replacement" claim]
Overall, the Humulin case is best read as a major extension of biotechnology rather than the moment biotechnology “began”. It is a strong bridge example for the syllabus because it shows the field operating across the past–present–future trajectory simultaneously: traditional extraction, then molecular engineering, and now further analogue design. The broader definition of biotechnology must accommodate both ends of this trajectory so that later ethical and biodiversity evaluations cover the whole field. [1 — justified overall judgement linked to syllabus trajectory; 1 — explicit terminology, named example used throughout]
Marking criteria.
- 1 mark — Defines biotechnology and explicitly identifies both traditional and modern branches.
- 1 mark — Correctly identifies animal-derived insulin as a form of traditional biotechnology and justifies the classification.
- 1 mark — Compares pipelines on molecular precision (recombinant identical to human insulin vs animal 1–3 amino-acid difference / immunogenicity).
- 1 mark — Compares pipelines on a second criterion (scalability / supply / decoupling from livestock).
- 1 mark — Locates Humulin within the past–present–future trajectory of the field.
- 1 mark — Uses Humulin to test the "extension not replacement" claim, citing evidence (e.g. continued use of fermentation infrastructure, continued reliance on living cells).
- 1 mark — Reaches a justified evaluative judgement rather than a one-line conclusion.
- 1 mark — Uses precise lesson terminology throughout (biotechnology, traditional/modern, recombinant DNA, scope) with at least one named example per branch.
Q2 — Sample Band 6 response (8 marks), annotated
The syllabus defines biotechnology as the use of living organisms, cells or biological processes to make products or solve problems in agriculture, medicine and industry, covering both traditional practices (e.g. fermentation, selective breeding) and modern molecular techniques (e.g. recombinant DNA, gene editing). The student’s claim that “biotechnology is basically just CRISPR” collapses this two-branch definition into one technology and is therefore wrong on the lesson’s own terms. [1 — definition and direct rejection of the claim]
Quantitatively, the student’s own table refutes the claim. Total market = 520 + 125 + 95 + 70 + 38 ≈ 848 USD bn. Purely modern medical biotechnology (the gene-editing / recombinant sector) represents about 520/848 ≈ 61%, leaving roughly 39% of the field outside that one sector. Within agriculture (~125 bn, ~15%), selective breeding and marker-assisted breeding are classified as “mixed”, meaning traditional methods are still active. Food and beverage fermentation alone (~70 bn, ~8%) is classified as purely traditional — bread, beer, wine, yoghurt and cheese are biotechnology by the syllabus definition. [1 — quantitative test using at least three rows of data]
Named examples across sectors confirm the same point. In medicine, recombinant insulin and mRNA vaccines are modern biotechnology. In agriculture, Bt cotton (engineered) and the centuries-old selective breeding of Merino sheep are both biotechnology. In food and beverage, sourdough bread, beer brewing and yoghurt fermentation continue without any genetic manipulation but still fit the definition. In industry, fermentation produces ethanol biofuels and many enzymes are made in engineered microbes — old and new methods running in parallel. [1 — named examples in three or more sectors; 1 — explicit traditional / modern split per sector]
Excluding traditional biotechnology from the definition would distort later evaluations in two specific ways. First, biodiversity discussions would be skewed: domestication and selective breeding have shaped global agricultural biodiversity (loss of crop landraces, the rise of monoculture cultivars like the Cavendish banana) over millennia, and any evaluation of biodiversity that ignores this misses the largest single human impact on it. Second, ethical evaluation would be dishonest: it is easy to defend “biotechnology is risky” or “biotechnology is beneficial” if biotechnology is collapsed to CRISPR alone, but a syllabus-honest evaluation must cover beer brewing, Bt cotton and CRISPR therapies in one frame. [1 — biodiversity reason; 1 — ethics reason]
A defensible reformulation: “Biotechnology is the use of biological systems for human purposes across agriculture, medicine, industry, food and the environment. Modern molecular tools such as CRISPR represent the most recent extension of a field with roots in fermentation, domestication and selective breeding stretching back thousands of years. Any evaluation of biotechnology’s social, ethical or biodiversity impact must include both branches.” [1 — defensible reformulation that uses the past–present–future framing]
Overall, the student’s claim is factually inconsistent with their own data and with the syllabus definition. Approximately 39% of the global biotechnology market and most of biotechnology’s history would be erased by their definition. The lesson’s broad definition is therefore not just an accident of curriculum design but a precondition for honest evaluation. [1 — justified overall evaluation linked to the syllabus framing]
Marking criteria.
- 1 mark — Defines biotechnology at syllabus level (both branches) and explicitly rejects the “CRISPR only” claim.
- 1 mark — Uses at least three rows of the table to test the claim quantitatively (percentages or ratios stated).
- 1 mark — Provides named biotechnology examples in three or more different sectors.
- 1 mark — Identifies both traditional and modern examples within at least one sector (e.g. Bt cotton + selective breeding in agriculture).
- 1 mark — Explains a specific way excluding traditional biotech would distort biodiversity evaluation.
- 1 mark — Explains a specific way excluding traditional biotech would distort ethical evaluation.
- 1 mark — Reformulates the claim into a biologically defensible statement that uses past–present–future framing.
- 1 mark — Reaches an integrated overall evaluative judgement using precise lesson terminology throughout.